Tag

Tagged: commentary

Sponsored

Diabesity and the food-brain relationship

Scientists from Imperial College London have enhanced our understanding of the food-brain relationship by discovering a brain mechanism that drives our appetite for foods rich in glucose, which could lead to treatments for diabesity.

Obesity, insulin resistance, metabolic syndrome and type-2 diabetes have reached epidemic proportions, yet few people understand how closely they're related, and what causes them. Diabesity is a metabolic dysfunction that ranges from mild blood glucose imbalance to fully-fledged type-2 diabetes.


Intimate food-brain relationship

Diabesity accounts for between 65 and 85% of new cases of type-2 diabetes, and affects more than one billion people worldwide; including 60 million Europeans, and 100 million Americans.

For most people, neither dieting nor current pharmacological interventions are effective in achieving long-term weight reduction. Therefore, to prevent and treat diabesity we must develop approaches to modulate the ways in which the brain controls body weight.

"This is the first time anyone has discovered a system in the brain that responds to a specific nutrient, rather than energy intake in general, and it raises the potential that diabesity could be reduced and prevented by medication acting on the part of the brain that craves glucose," says Dr James Gardiner who led the study.

Our brain rules our belly
Researchers identified a mechanism, which senses how much glucose is reaching our brain, and if our brain detects a shortfall, it makes prompts to seek more glucose. This mechanism is more active in people who are obese-prone, suggesting that the brain can promote obesity.

The Imperial College study is published in The Journal of Clinical Investigation . According to its lead author, Dr Syed Sufyan Hussain, 'Glucose is a component of carbohydrates, and the main energy source used by brain cells. This study demonstrates that the brain plays a significant role in driving our preference for sweet and starchy foods. Prior to industrialisation, such glucose rich foods were not easily available, but today they're everywhere.'

Addicted to food?
Dr Mohammed Hankir, a neuroscientist at the University of Leipzig, Germany, says, 'It's becoming increasingly clear that when we consume certain types of food, particularly those high in fat and sugar, the same brain circuits are engaged as when taking drugs of abuse. We may therefore have little choice about overeating and becoming obese.'

If the diabesity epidemic is the result of our brains being hard-wired to consume energy rich food, can we cure diabesity with pharmacological manipulation of these brain pathways?

Bowels control the brain
Professor Sir Stephen Bloom, Head of Division for Diabetes, Endocrinology and Metabolism, Imperial College London, thinks we can, and says, 'Gut hormones are chemical messengers secreted by the digestive system that affect our brain and control appetite. Hijacking this natural messenger system is an attractive and likely option for treating diabesity'. The GLP-1 hormone is widely used for the treatment of diabetes. It also leads to weight loss. There are other such gut hormones that need further evaluation because they could provide attractive solutions for obesity. 
 
Takeaways
The food-gut-brain relationship promises a much-needed solution for the diabesity epidemic. Whilst the search continues, we must act now to prevent this. Most healthcare systems are organized to treat the acute symptoms of diabesity, and manage the condition once it's been diagnosed. Healthcare systems are less adept at prevention, and early detection. This requires effective education, which is currently not available. 

 

view in full page

 

 
What causes breast and oral cancer, heart disease, strokes, liver cirrhosis, depression, memory impairment and reduced fertility? . . . . . . . . Alcohol.

More dangerous than heroine

NHS figures show that alcohol related hospital admissions peaked in 2010 when over a million people were admitted. Alcohol Concern predicts that by 2015, the annual number of hospital admissions due to alcohol will reach 1.5m, and cost the NHS £3.7bn a year. A 2010 study in The Lancet suggests that alcohol is more dangerous than heroine. A study by the Independent Scientific Committee on Drugs agrees, and ranks alcohol as three times more harmful than cocaine or tobacco.

The WHO's 2014 Global Status Report on Alcohol and Health said that in 2012 there were 3.3m alcohol related deaths worldwide, and called on governments to implement policies to reduce the harmful use of alcohol.
 
 
˜Yes minister" government response
The UK government guidelines on drinking are being reviewed. Currently, they suggest hat a women should not drink more than two to three units of alcohol per day, and a man three to four units. But medical experts argue that people don't realise how much they're drinking.

Liver
Although the toxicity of alcohol is complex, there's a significant relationship between the greater the alcohol intake per week, and the greater the liver damage.  Over the past 25 years, UK deaths from liver disease have increased by 500%; the overwhelming majority alcohol related. Only in the last few years has this increase slowed. Alcohol has a bigger impact than smoking on health because alcohol kills at a younger age. The average age of death for someone with alcoholic liver disease is their 40s.

Heart
Moderate alcohol consumption raises good cholesterol, stops the formation of blood clots in the arteries, and helps protect against heart disease. Drinking more than three drinks a day has a direct and damaging effect on the heart. Heavy drinking, particularly over time, can lead to high blood pressure, alcoholic cardiomyopathy, congestive heart failure and stroke. Heavy drinking also puts more fat into the circulation of the body, which is dangerous for the heart.
 
Cancer
The link between alcohol and cancer is well established. Cancer occurs when DNA is altered. Acetaldehyde is a toxic created when alcohol in the liver is broken down by an enzyme, and has been shown to damage DNA. When you drink, the acetaldehyde corrupts DNA. One of the most common genetic defects in man is our inability to counteract the toxicity of alcohol.
 
A 2011 study published in the British Journal of Medicine estimates that alcohol consumption causes at least 13,000 cancer cases in the UK each year. Cancer experts say that for every additional 10g per day of alcohol drunk, the risk of breast cancer increases by approximately seven to 12%.

Other conditions
Studies also show that increasing alcohol intake by 100g per week increases bowel cancer risk by 19%. A recent report in BioMed Central's Immunology Journal found that alcohol impairs the body's ability to fight off viral infections. Studies on fertility suggest that even light drinking can make women less likely to conceive while heavy drinking in men can lower sperm quality and quantity.

Takeaway
It's time for governments to implement policies to reduce the harmful effects of alcohol.
view in full page
 
In 2015 expect increasing healthcare challenges from (i) aging populations and rising chronic illnesses, (ii) escalating costs and patchy quality, (iii) access, (iv) changing technologies, and (v) security. 
 
Aging populations and chronic illness
Aging populations and the escalating prevalence of chronic lifelong diseases, will drive demand for healthcare in 2015, and impose significant burdens on healthcare systems.
 
Europe has the world's highest proportion of people over 60. By 2017, 20% of Europeans will be over 65. By 2050 about 40% will be over 60. The US has similar trends. This aging and the increasing prevalence of chronic lifestyle diseases will continue to drive healthcare expansion, and pressure to reduce healthcare costs.  
 
Escalating costs and patchy quality
According to the World Healthcare Outlook of the Economist Intelligence Unit 2014, total global health spending is expected to grow at over 5% in 2015.
 
In Europe rising government debts, constraints on tax revenues, and aging populations will force health providers to make difficult choices about the provision of healthcare. Rising demand, and continued cost pressures will increase pressure on traditional healthcare business models and operating processes to change.
 
Despite the expected annual productivity and efficiency savings of some 4%, UK healthcare expenditure in 2015 is estimated to be about 10.3% of GDP. In the absence of changes to the delivery model, the UK's NHS funding gap is likely to increase significantly in 2015.
 
In their struggle to manage the escalating healthcare costs, health providers will accelerate their transition from volume to value. This will mean a greater emphasis on improving outcomes while lowering costs. This will drive payers to seek out global best practices of delivering affordable quality healthcare such as Narayana Health.
 
Access 
Improving access to healthcare will be one of the most pressing policy issues in 2015. Shortages of health professionals represent significant challenges in healthcare access, and healthcare systems will be pressed to recruit, and retain health professionals.The US is addressing this. US employment in healthcare increased from 8.7% of the civilian population in 1998 to 10.5% in 2008, and is projected to rise to 11.9% (nearly 20 million people) by 2018.
 
The UK is not in such a good position. In 2012 the UK had a shortage of 40,00 nurses, which it hasn't resolved. This is compounded by shortages GPs. Europe has an estimated shortage of some 230,00 doctors.
 
Increasingly, developed countries recruit health professionals from developing economies. The morality of this will be further questioned in 2015 as the policy significantly erodes the number and quality of healthcare professionals in emerging countries.
 
Changing technologies
The development of healthcare technologies has been rapid, and in some cases disruptive. Technologies such as telemedicine, electronic health records, mHealth, e-prescriptions, and predictive analytics have changed the way health providers, payers and patients interact, and contributed to improved quality of care, lower costs and improved outcomes. In 2015 expect the spend on healthcare technologies to slow.  
 
Security    
Reportedly, there is a growing and lucrative black-market for personally identifiable information, and personal healthcare information. Many healthcare organizations already have low security budgets, and only about 50% employ adequate encryption technologies to secure their endpoint data. Compared with other industries, healthcare experiences significant losses of endpoint healthcare data. Security challenges for the healthcare sector will accelerate in 2015. 
view in full page
 
Structured educational courses to help people living with diabetes manage their condition are not working.
 
A few closed service providers dominate diabetes education in the UK, and according to the last National Diabetes Audit, less than 2% of the 3.8 million diagnosed with diabetes attend any form of structured education.
 
The non-dramatic, insidious and chronic nature of diabetes masks the fact that it has become a global epidemic with the potential to overwhelm national health systems, if education can't halt its progress. 
 
Although advances in diabetes research are significant, the horizon for a cure is still distant. At this moment in time, the best option to halt the progression of diabetes is convenient, fast and effective education.
 
 
Diabetes education and outcomes
Current providers of diabetes education fail to demonstrate how their offerings affect outcomes, and people are not interested in educational courses if they're not linked to outcomes. A 2012 London School of Economics study concludes that there's a lack of diabetes outcome data in the UK, and, "No one really knows the true impact of diabetes, and its associated complications."

The 2013 Annual Report of Diabetes UK (DUK) states that 50,000 people with diabetes used the Charity's blood glucose tracker app, 500,000 took its diabetes risk test, and DUK distributed 250,000 foot-guides, but the Report fails to mention what impact these important activities had on patient outcomes. 
 
Shift of power
Traditional providers of diabetes education have yet to appreciate that the information age has shifted the balance of power from health providers to patients.
 
Mobile devices are ubiquitous and personal. By 2018 smartphone penetration in the UK is expected to be 100%. The over 55s are projected to experience the fastest year-on-year smartphone penetration, and the difference of smartphone penetration by age is expected to disappear by 2020. Further, competition will continue to drive down prices of mobile devices, and increase their functionality. 
 
Over 70% of people living with diabetes regularly use their mobiles to search the Internet for healthcare information, and use social-media to share information about health providers, and educational courses.  This is carried out 24-7, 365 days a year.
 
Traditional providers of diabetes educational courses should be minded that 35% of all patients who use social-media say negative things about health providers, 40% of people who receive such negative information believe it, and 41% say it affects their choices. Social-media is the new frontier of reputation risk for providers of diabetes education.
 
Takeaways
Traditional providers of diabetes education must become more open to independent service providers, and enhance their digital strategies to make their education offerings smarter, faster, and better. 
view in full page
 
A new test, called ADNEX, reported in the British Medical Journal in October 2014 helps to identify different types and stages of ovarian cancer more accurately, which scientists claim will reduce the incidences of unnecessary surgeries. 
 
Accurate, simple and ready
The test, developed by an international team led by Imperial College London and KU Leuven, Belgium, is based on patient data, a simple blood test, and features that can be identified on an ultrasound scan. Doctors can use it simply by entering patient data into a smartphone app. It's highly accurate, and discriminates between benign and malignant tumours, and also identifies different types of malignant tumours.
 
Successful treatment depends on accurate diagnosis, and diagnosis of ovarian cancer can be challenging. According to Professor Tom Bourne, Department of Surgery and Cancer at Imperial College London, "The way we assess women with ovarian cysts for the presence of cancer and select treatment lacks accuracy. This new approach to classifying ovarian tumours can help doctors make the right management decisions, which will improve the outcome for women with cancer. It will also reduce the likelihood of women with all types of cysts having excessive or unnecessary treatment that may impact on their fertility.
 
Frequently misdiagnosed
The frequent misdiagnosis of ovarian cancer means that it often presents late when it has already metastasized. It's the most aggressive gynecological malady, with poor survival rates: only 40% survive beyond five years, and it can affect any woman.
 
The reason why early symptoms are difficult to detect is because inside the abdomen, the ovary has a lot of space to grow into before it starts to press onto other structures such as the uterus, bowel and bladder.
 
Early detection is key
All women should be on guard of the symptoms, which may be vague at first, and similar to other conditions, such as digestive disorders. The commonest symptoms are discomfort or pain in the lower abdomen or pelvis, and also there may be backache or a swelling felt.
 
There is a survival rate of up to 90% when ovarian cancer is caught early, compared with less than 30% if it is discovered in the later stages. 
 
Increasing incidence in younger women
Around 1 in 55 women will get ovarian cancer at some time in their life, and it is more common over the age of 40. Less than 1 in 20 ovary cancers occur in women younger than this. There are inherited factors involved in some cases, and research is underway to find out how best to screen women at increased risk of the disease. Since the mid-1970s, the incidence of ovarian cancer in women between 15 and 39 has increased by some 56%.
 
Takeaway
Currently, early detection, and rapid referral to a specialist gynaecological cancer unit is the key to transforming survival rates for ovarian cancer. Patients therefore have to rely on seeing a doctor, and being correctly diagnosed in time. 
 
view in full page
 
In October 2014 Harvard professor Douglas Melton announced a breakthrough in the treatment of type-1 diabetes by creating stem cells that produce insulin.

Melton demonstrated that mice treated with transplanted pancreatic cells are still producing insulin months after being injected. Testing in primates is now underway at the University of Chicago, and clinical studies in humans should begin in just a few years.

"Most patients are sick of hearing that something's just around the corner," says Melton, but he's convinced that his research represents a significant turning point in the fight against diabetes.

Type-1
Type-1 diabetes, which usually occurs in children, is an autoimmune disease in which the body attacks its own beta cells of the pancreas and destroys their ability to make insulin. It's a devastating lifelong chronic condition, which affects some three million Americans and 400,000 English people. Treatment is daily insulin doses, a healthy diet and regular physical activity.
 
Increasing incidence
For reasons not completely understood, the incidence of type-1 diabetes has been increasing throughout the world at about three to five per cent a year, and is most prevalent in Europe. This is troubling, because type-1 diabetes has the potential to disable or kill people early in their lives.

The search to discover why type-1 diabetes is increasing resembles the penultimate chapter of an Agatha Christie mystery, where there are many suspects, but no prime candidate. The last chapter to explain the increasing incidence of type-1 diabetes is yet to be written.  
 
Parents unaware of symptoms
A 2012 UK report suggests that parents are unaware of the warning signs of type-1 diabetes: thirstiness, tiredness, weight loss and frequently passing urine. As a consequence 25% of children with the condition are diagnosed once they are already seriously ill with diabetic ketoacidosis (DKA). DKA occurs because a severe lack of insulin upsets the body's normal chemical balance, and leads to the production of poisonous chemicals called ketones. This build-up can be life threatening, and needs immediate specialist treatment in hospital.
The challenge of cell production
Making industrial quantities of the insulin-producing cells of the pancreas has been a Holy Grail of diabetes research. All previous attempts have failed to achieve scalable quantities of the mature beta cells that could be of practical benefit to people living with diabetes.

Just over 20 years ago when Professor Melton's son Sam was diagnosed with type-1 diabetes Melton promised that he would find a cure. He was further inspired when his daughter at 14 was also diagnosed with type-1 diabetes.

According to Melton, it should be possible to produce 'scalable' quantities of beta pancreatic cells from stem cells in industrial-sized bioreactors, and then transplant them into a patient to protect them from immune attack. This would result in an effective cure.

"The biggest hurdle has been to get glucose-sensing, insulin-secreting beta cells, and that's what our group has done," says Melton.

In addition to offering a new form of treatment, and possibly a 'cure' for type-1 diabetes, Melton believes his discovery could also offer hope for the 10% of people living with type-2 diabetes who have to rely on regular insulin injections.

Takeaway
If Professor Melton is successful, not only will his discovery honour a promise to his children, but also it'll be a medical game-changer on a par with antibiotics and bacterial infections.
view in full page
 
Was the UK Department of Health (DH) right to axe its telehealth project?

Telehealth
Telehealth is a combination of medical devices and communication technology used to monitor diseases and symptoms, and support health and social care remotely. It represents a solution to the challenges of rising healthcare costs, an aging population, and the increasing prevalence of chronic diseases.

The Whole Systems Demonstrator Project
The DH's Whole Systems Demonstrator (WSD) project was an ill-conceived top-down endeavour doomed to fail. It cost £31m, and was the world's largest randomised control trial of telehealth involving 7,000 patients, 240 primary care practices across three UK sites.
 
3millionpeople
In 2011 an interim evaluation concluded that the WSD project could achieve a 45% reduction in mortality rates, a 15% drop in A&E visits, a 14% reduction in bed-days, and an 8% reduction in tariff costs.

These estimates are in line with international findings. Based on a review of some 2,000 studies, GlobalMed concludes that telehealth has reduced hospital re-admissions by 83%, decreased home nursing visits by 66%, and lowered overall costs by more than 30%. Nothing else has worked to reduce such costs.
 
It was projected that by 2017 three million people in England with long term conditions would be recording their medical data and vital signs remotely, and sending them, via email and text, directly to GPs. This could save the NHS £1.2 billion a year, and significantly enhance the quality of patient care.
 
GP's wrath should have been expected
Despite its projected success, the DH's telehealth project was quietly axed, following a London School of Economics (LSE) study, which concluded that the project, "does not seem to be a cost-effective addition to standard support and treatment", and GPs complaining of a "tsunami" of data.
 
Too much importance was given to the LSE study, and not enough to GPs. The DH failed to understand how to change a large healthcare system. As a consequence the UK telehealth project was a bolt on to a poorly integrated care system not adapted to telehealth, and was sure to incur the wrath of GPs.

Despite endeavours to train more GPs and expand community nurses, there is abundant evidence to suggest that GPs struggle under large and growing workloads, and reports of stress and burnout are common. Not a group you would impose change upon from the top. 
A human system which uses technology
The DH wrongly viewed telehealth as a technology system, and healthcare as a machine with processes and activities that delivers services to patients. Telehealth is a human system, which uses technology.

Health professionals, patients and their carers are the essential tools of telehealth. As they become more experienced in collecting, analysing and acting upon the information they receive from telehealth devices, so they become more integrated, and patients benefit and cost effectiveness increases.

Lessons for the DH
  1. Healthcare is an organic system comprised of people operating in a context
  2. Change is non-linear
  3.  GPs are not commodities on which to impose change from the top, but sources of power, which can bring about change
  4. Seeds of change should have been planted with GPs who perceive change as an opportunity for personal development and growth.  
 
Takeaway
The DH was right to axe its badly conceived telehealth project, but would be wrong to withdraw its support for telehealth.  
view in full page
 
Diabetic foot ulcers (DFU) are responsible for more hospitalizations than any other complication of diabetes, and the biggest cause of amputation. Of the 26 million people in the US, and some 3.8 million in the UK diagnosed with diabetes, as many as 25% may experience a DFU in their lifetime. 
 
People living with diabetes are at risk of nerve damage (neuropathy), and problems with the blood supply to their feet (ischaemia). Nerve damage results in a reduced ability to feel pain, and therefore injuries often go un-noticed. Ischaemia can slow down wound healing. Both ischaemia and neuropathy can lead to DFUs. Infections in DFUs can lead to amputation.
 
The burden of DFUs
DFUs impose a substantial burden on public and private payers, doubling care costs per patient compared with diabetic patients without foot ulcers. In the US, ulcer care adds around US$9 to US$13 billion to the direct yearly costs associated with diabetes, and in the UK, around £650 million is spent on DFUs and amputations each year.
 
The five-year recurrence rates of DFUs are as high as 70%. People with diabetes with one lower limb amputation have a 50% risk of developing a serious ulcer in the second limb within two years. People with diabetes have a 50% mortality rate in the five years following an initial amputation. These numbers have not changed much in the past 30 years, despite significant advances in the medical and surgical therapies for people with diabetes.
  
Poorly understood pathology
The exact mechanism by which diabetes impairs wound healing is not fully understood, and as a result, the management of DFUs is challenging, and has been a neglected area of healthcare research and planning. Current clinical practice is based more on opinion than scientific fact.
 
According to Hisham Rashid, a consultant vascular surgeon at Kings College Hospital, London who specializes in the surgical therapy for DFUs,  "Because the pathological processes of DFUs are complex, they tend to be poorly understood, and communication between the many specialties involved can be disjointed and insensitive to the needs of patients. One of the biggest recent improvements in foot care has been the close liaison of different specialties in multidisciplinary foot clinics."
Advances in therapeutics
Surgeons have tended to use free tissue transfer, as the treatment of choice for complex DFUs, but the length and intricacies of these procedures is contraindicated, and can lead to complications. This has led surgeons to turn to bioengineered alternative tissue in the reconstruction of these complex wounds.

One new bioengineered tissue for DFUs is an advanced bilayer skin replacement system designed to provide immediate wound closure, and permanent regeneration of the dermis. The product, Integra Dermal Regeneration Template, recently completed a clinical study, and an initial review suggests that the study has achieved its primary goal, which is complete wound closure at 16 weeks.

Takeaways
It's possible to reduce DFUs and consequent amputation rates by as much as 49 to 85%. This can be achieved through a care strategy, which combines prevention, close monitoring and education. According to Rashid, "Health professionals have an important role to play in enhancing the education for people living with diabetes in order to propel them towards self-management, and slow the onset of complications such as DFUs."
view in full page
 
Evidence from a recent survey of people with diabetes, suggests patient outcomes will improve if GPs provide healthcare information in video clips rather than paper pamphlets.

Traditional patient information is failing
"An indication that the current paper and web-based diabetes information is failing to improve patient outcomes is the fact that the incidence rates of diabetes in the UK are escalating. Currently, a plethora of diabetes information is provided either in paper pamphlets or as digitalized text on websites, but patients want healthcare information in video clips, and greater connectivity with their health providers," says Dr Seth Rankin, managing partner, Wandsworth Medical Centre, who conducted the survey.

Despite the NHS spending £10 billion each year on diabetes care, between 2006 and 2011 the number of people diagnosed with diabetes in England increased by 25%: from 1.9 million to 2.5 million. Today, 3.8 million people have diabetes, and this number is expected to increase to 6.2 million by 2035. In 2013 there were 163,000 new diagnoses of diabetes in the UK, the biggest annual increase since 2008, and the five-year recurrence rates of diabetic foot ulcers are as high as 70%. The population increase over the past decade only explains some of these increases.
 
 
Improving outcomes
Organizations treat the distribution of diabetes information as ends in themselves, and report the quantity of information distributed, but not the impact it has on outcomes.
 
By simply asking patients with diabetes how, when and where they would like to receive information to help them manage their condition provides an important missing social link between health professionals and patients, and can help to improve outcomes.
 
Patients' views neither sought nor acted upon
"When we ask patients living with diabetes," says Rankin, "we get a clear picture of what patients want. The fact that patients' opinions are rarely sought, and even more rarely acted upon, might help to explain why the incidence rates of diabetes are escalating. There's no shortage of resources and technical competences in the UK to treat and manage diabetes. However, communications between doctors and their patients living with diabetes throughout their therapeutic journeys are weak. This inhibits patient education, slows self management and quickens the onset of complications," says Rankin. 
 
Patient survey 
In 2014, 140 people living with diabetes from two London primary care practices participated in a six-week project to improve doctor-patient communications. Patients received regular video clips via email from their health professionals and fellow patients to help them improve the management of their condition. At the end of the project patients' opinions were sought in an email survey, which yielded 51 responses: a response rate of 36%.
 
Findings
  • 65% found video information about diabetes helpful
  • 72% prefer diabetes information from GPs via email
  • 70% want access to healthcare information anytime, anywhere and anyhow 
  • 52% prefer healthcare information in video format to paper pamphlets
  • 68% want more information about their condition
  • 14% visit Diabetes UK's website
  • 53% regularly search the Internet for information about diabetes care
  • Only 19% can distinguish between good and bogus Internet healthcare information
 
Takeaways
"Providing diabetes information in short video clips featuring local health professionals, which can be easily browsed by patients, creates greater connectivity between doctors and patients.
Unlike health professionals and paper pamphlets, video clips never wear out, and are available 24-7, 365 days a year. Further, any number of people can access them at the same time, from anywhere, on any device.
Our survey suggests that videos clipsare effective in increasing patients' knowledge of diabetes, and propelling them towards self-management. Video clips could be used for all manner of patient information on all manner of conditions," says Rankin.
view in full page
 

In July 2014 the European Translational Research Network in Ovarian Cancer (EUTROC), held its annual conference in London. High on its agenda was cancer's resistance to established drugs.

Cancer is a complex disease. It arises from random "errors" in our genes, which regulate the growth of cells that make-up our bodies. Error-laden cells either die or survive, and multiply as a result of complex changes that scientists don't fully understood.
 
Translational medicine
Translational medicine is a rapidly growing discipline in biomedical research, which benefits from a recent technological revolution that allows scientists to monitor the behaviour of everyone of our 25,000 genes, identify almost every protein in an individual cell, and work to improve cancer therapies.
 
Ovarian cancer is the forth most common form of cancer in women, after breast, lung and bowel cancer. Each year, in the UK some 7,000 people are diagnosed with ovarian cancer, in the US it's 240,000. Most women are diagnosed once the cancer has spread beyond the ovaries, which makes treatment challenging, and mortality rates high. Only 10% of women diagnosed with ovarian cancer at the latest stage survive more that five years. 
 
 
Molecular profiling
EUTROC employs a multi-disciplinary, collaborative, "bench-to-bedside" approach in order to expeditiously discover new therapies, which tailor medical treatment to the specific characteristics of specific cancers: personalised medicine.
 
Cancers are like people: not all are alike, and when examined at a molecular level they show that their genetic makeup is very different. Clinicians use molecular profiling to examine the genetic characteristics of a person's cancer as well as any unique biomarkers, which enables them to identify and create targeted therapies designed to work better for a specific cancer profile.
 
Combatting cancer resistance
Personalising treatment to target errors in specific cancers at the point of diagnosis fails to address the fact that cancers mutate in response to treatment. Even drugs that are initially effective may become ineffective as the cancer returns and re-establishes its ability to grow and spread. Cancer often behaves like a taxi navigating a way round a localised traffic jam

 

An approach to combat this is to treat a cancer with one target drug, and if the cancer returns with newly developed resistance, identify how that resistance occurred and target that with another drug, and so on, until the cancer and its resistances are beaten.  This is similar to accepting that a local traffic jam may be bypassed, and finding and blocking all the ways around the jam.
 
Another approach is to target and block something critical for the survival of a specific cancer. This is similar to blocking a strategic point that controls all the traffic coming in and leaving a city. For example, taxi drivers clogging up Trafalgar Square and bringing London to a standstill. But scientists are a long way from achieving this because researchers don't know whether such targets in relations to cancers exists, and even if they did, they don't know whether they can be blocked effectively. And, even if such targets were discovered and were blocked, scientists still don't know what would be the side effects of doing so. 
 
Takeaways
For personalised medicine to be successful, clinicians and scientists need to track the evolutionary trajectories of cancers in patients through sequential episodes of treatment and relapse. Besides being a major clinical and scientific challenge, this is also a significant informational and communication challenge, which networks such as EUTROC are addressing.
view in full page